全球胆管癌治疗市场规模、份额、趋势和成长分析报告（2026-2034）

预计胆管癌治疗市场规模将从 2025 年的 2.6917 亿美元增长到 2034 年的 5.3094 亿美元，并预计从 2026 年到 2034 年将以 7.84% 的复合年增长率增长。

由于胆管癌（胆管细胞癌）发生率低且诊断往往较晚，其治疗市场历来小规模。然而，随着标靶治疗和免疫肿瘤药物的出现，该领域再次受到关注。儘管化疗多年来一直是标准治疗方法，但基因组分析发现了可治疗的突变（例如IDH1和FGFR2融合），从而推动了标靶抑制剂的研发和特定适应症的核准。肿瘤中心分子检测的普及提高了可治疗亚型的诊断率，扩大了目标患者群体，也吸引了投资者的目光。

精准肿瘤学的进步、标靶药物的监管核准以及分子诊断的普及是推动成长要素。在肿瘤网络和患者权益组织的推动下，全球临床试验活动显着增加。这加速了适应症的扩展以及特定族群的仿单标示外用药。伴随诊断和基于生物标记的患者招募提高了研发效率，即使患者绝对数量较少，市场也正向高附加价值的专科疗法转型。

未来前景谨慎但乐观。持续发现可治疗的突变以及与免疫疗法的联合策略有望拓展治疗选择并提高存活率。市场扩张取决于基因组检测的广泛应用、昂贵标靶药物的报销政策以及后期临床试验的成功，这些试验需证实药物的持续疗效。由于该疾病罕见，预计患者单次治疗费用高昂，标靶治疗之间存在竞争，因此需要重视伴随诊断和真实世界数据以促进药物推广。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球胆管癌治疗市场：依标靶治疗划分

• 市场分析、洞察与预测
• 培米加替尼
• Infigratinib（3期试验）
• Ivosidenib（3期试验）
• 免疫疗法（Pembrolizumab（3期临床试验））
• 其他的

第五章 全球胆管癌治疗市场：依应用划分

• 市场分析、洞察与预测
• 医院
• 诊所
• 其他的

第六章：全球胆管癌治疗市场：依适应症划分

• 市场分析、洞察与预测
• 肝内胆管癌
• 肝外胆管癌

第七章 全球胆管癌治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球胆管癌治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Johnson & Johnson Private Limited
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • GlaxoSmithKline Plc
  • AbbVie Inc
  • Novartis AG
  • Fresenius Kabi AG
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Intercept Pharmaceuticals
  • Kyowa Kirin Co. Ltd
  • Delcath Systems Inc

The Bile Duct Cancer Drug Market size is expected to reach USD 530.94 Million in 2034 from USD 269.17 Million (2025) growing at a CAGR of 7.84% during 2026-2034.

The bile duct (cholangiocarcinoma) drug market has historically been small due to disease rarity and late-stage diagnosis, but it has seen renewed interest as targeted therapies and immuno-oncology agents emerge. Traditional chemotherapy remained the standard for years, but genomic profiling revealed actionable mutations (IDH1, FGFR2 fusions, etc.), prompting development of targeted inhibitors and niche approvals. Increased molecular testing at oncology centers has elevated diagnosis of targetable subtypes, expanding addressable patient populations and investor interest.

Primary growth drivers are advances in precision oncology, regulatory approvals of targeted agents, and expanding access to molecular diagnostics. Clinical trial activity has increased globally, supported by oncology networks and patient advocacy; this has accelerated label expansions and off-label use in select populations. Companion diagnostics and biomarker-driven enrollment have made development more efficient despite small absolute patient numbers, shifting the market toward high-value, specialized therapies.

Future prospects are cautiously optimistic: continued identification of actionable mutations and combination strategies with immunotherapies could broaden therapeutic options and improve survival. Market expansion depends on wider availability of genomic testing, reimbursement policies for expensive targeted agents, and successful late-stage trials demonstrating durable benefit. Given the orphan nature of the disease, expect high per-patient pricing, rising competition among targeted therapies, and an emphasis on companion diagnostics and real-world evidence to support uptake.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Targeted Therapy

• Pemigatinib
• Infigratinib (Phase 3)
• Ivosidenib (Phase 3)
• Immunotherapy (Pembrolizumab (Phase 3))
• Others

By Application

• Hospitals
• Clinics
• Others

By Disease Indication

• Intrahepatic Bile Duct Cancer
• Extrahepatic Bile Duct Cancer

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson Johnson Private Limited, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, AbbVie Inc, Novartis AG, Fresenius Kabi AG, Eli Lilly and Company, F HoffmannLa Roche Ltd, Intercept Pharmaceuticals, Kyowa Kirin Co Ltd, Delcath Systems Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BILE DUCT CANCER DRUG MARKET: BY TARGETED THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Targeted Therapy
• 4.2. Pemigatinib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Infigratinib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ivosidenib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunotherapy (Pembrolizumab (Phase 3)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BILE DUCT CANCER DRUG MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Indication
• 6.2. Intrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Extrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BILE DUCT CANCER DRUG MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Targeted Therapy
  • 8.2.2 By Application
  • 8.2.3 By Disease Indication
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Targeted Therapy
  • 8.3.2 By Application
  • 8.3.3 By Disease Indication
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Targeted Therapy
  • 8.4.2 By Application
  • 8.4.3 By Disease Indication
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Targeted Therapy
  • 8.5.2 By Application
  • 8.5.3 By Disease Indication
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Targeted Therapy
  • 8.6.2 By Application
  • 8.6.3 By Disease Indication
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BILE DUCT CANCER DRUG INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Johnson & Johnson Private Limited
  • 10.2.2 Mylan N.V
  • 10.2.3 Teva Pharmaceutical Industries Ltd
  • 10.2.4 Sanofi
  • 10.2.5 Pfizer Inc
  • 10.2.6 GlaxoSmithKline Plc
  • 10.2.7 AbbVie Inc
  • 10.2.8 Novartis AG
  • 10.2.9 Fresenius Kabi AG
  • 10.2.10 Eli Lilly And Company
  • 10.2.11 F. Hoffmann-La Roche Ltd
  • 10.2.12 Intercept Pharmaceuticals
  • 10.2.13 Kyowa Kirin Co. Ltd
  • 10.2.14 Delcath Systems Inc